These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 26100706

  • 1. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
    VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN, Samuelsen Ø, Jakobsen L, Småbrekke L, Andersson DI, Sundsfjord A, Frimodt-Møller N.
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
    [Abstract] [Full Text] [Related]

  • 3. In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [Abstract] [Full Text] [Related]

  • 4. Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.
    VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG.
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5141-5. PubMed ID: 27270274
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
    Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB.
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
    Zhanel GG, Parkinson K, Higgins S, Denisuik A, Adam H, Pitout J, Noreddin A, Karlowsky JA.
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):271-275. PubMed ID: 28483306
    [Abstract] [Full Text] [Related]

  • 7. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.
    Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB, Landersdorfer CB, Bergen PJ.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1570-1578. PubMed ID: 29506207
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
    Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Mouton JW, Peleg AY.
    J Microbiol Methods; 2020 Apr 01; 171():105861. PubMed ID: 32035114
    [Abstract] [Full Text] [Related]

  • 9. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
    Abbott IJ, Meletiadis J, Belghanch I, Wijma RA, Kanioura L, Roberts JA, Peleg AY, Mouton JW.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):709-719. PubMed ID: 29253153
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.
    Ungheri D, Albini E, Belluco G.
    J Chemother; 2002 Jun 01; 14(3):237-40. PubMed ID: 12120876
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Mao J, Li T, Zhang N, Wang S, Li Y, Peng Y, Liu H, Yang G, Yan Y, Jiang L, Liu Y, Li J, Huang X.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0087121. PubMed ID: 34851157
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic studies of nitrofurantoin against common uropathogens.
    Komp Lindgren P, Klockars O, Malmberg C, Cars O.
    J Antimicrob Chemother; 2015 Apr 22; 70(4):1076-82. PubMed ID: 25515669
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
    Abbott IJ, van Gorp E, Wijma RA, Dekker J, Croughs PD, Meletiadis J, Mouton JW, Peleg AY.
    J Antimicrob Chemother; 2020 Jul 01; 75(7):1879-1888. PubMed ID: 32361749
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
    Diep JK, Sharma R, Ellis-Grosse EJ, Abboud CS, Rao GG.
    Antimicrob Agents Chemother; 2018 Feb 01; 62(2):. PubMed ID: 29203494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.